Core Viewpoint - The article highlights the serious issue of commercial bribery in the medical sector, emphasizing the need for stringent measures to combat it and protect public health and the integrity of the healthcare system [1][2][3]. Group 1: Cases of Bribery - The National Healthcare Security Administration (NHSA) reported a case involving a hospital director in Shaanxi who illegally accepted 2.72 million yuan in bribes, primarily from orthopedic consumables [1]. - This case is part of a broader trend, with the NHSA exposing multiple instances of bribery in the medical field, indicating a rampant issue that undermines fair competition and increases medical costs [1][2]. Group 2: Nature of Commercial Bribery - Commercial bribery in the medical field distorts prescription rights and interferes with normal medical practices, leading to increased costs for patients and the healthcare system [2]. - The bribery cases reveal a pattern where suppliers offer high rebates to secure contracts, which ultimately inflates product prices and burdens patients and insurance funds [2][3]. Group 3: Systemic Issues and Reforms - The article discusses the systemic issues that allow commercial bribery to persist, including complex interest chains and regulatory loopholes, particularly in high-value consumables and pharmaceuticals [2][3]. - The NHSA has been increasing efforts to combat commercial bribery through administrative and criminal measures, emphasizing the need for comprehensive reforms in the procurement system to reduce incentives for bribery [3][4]. Group 4: Recommendations for Action - To effectively eliminate commercial bribery, a multi-faceted approach is necessary, including strict penalties for both bribers and recipients, improved internal decision-making processes in medical institutions, and enhanced transparency in procurement [4][5]. - The article stresses the importance of enforcing the principle of "joint investigation of bribery and acceptance" and the "dual penalty system" for companies and individuals involved in bribery [4][6]. Group 5: Broader Implications - The prevalence of commercial bribery not only harms public finances but also jeopardizes public health and social equity, as each bribe can lead to unnecessary medical expenses and inappropriate treatment choices [6]. - The ongoing efforts to combat medical commercial bribery are crucial for purifying the industry and safeguarding the health and welfare of the public [6].